Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

September 02, 2015 1:23 AM ET


Company Overview of Ceragenix Pharmaceuticals, Inc.

Company Overview

Ceragenix Pharmaceuticals, Inc. operates as a medical device company focusing on dermatology and infectious diseases in the United States. The company has two base technology platforms, which include Barrier Repair for the treatment of dermatological disorders; and Ceragenins for the treatment of infectious disease. Its Barrier Repair technology is the platform for the development of two prescription topical creams, including EpiCeram, a prescription product for the treatment of dry skin conditions and to manage and relieve the burning and itching associated with various types of dermatoses, including eczema, irritant contact dermatitis, and radiation dermatitis; and NeoCeram, a pediatric ba...

1444 Wazee Street

Suite 210

Denver, CO 80202

United States

Founded in 2002

5 Employees





Key Executives for Ceragenix Pharmaceuticals, Inc.

Ceragenix Pharmaceuticals, Inc. does not have any Key Executives recorded.

Ceragenix Pharmaceuticals, Inc. Key Developments

SEC Orders Hearing On Registration Suspension Or Revocation Against Ceragenix Pharmaceuticals

In conjunction with trading suspension, the Securities and Exchange Commission (SEC) also instituted public administrative proceeding to determine whether to revoke or suspend for a period not exceeding twelve months the registration of each class of the securities of Ceragenix Pharmaceuticals, Inc. for failure to make required periodic filings with the Commission. In this Order, the Division of Enforcement (Division) alleges that the company is delinquent in its required periodic filings with the Commission. In this proceeding, instituted pursuant to Exchange Act Section 12(j), a hearing will be scheduled before an Administrative Law Judge. At the hearing, the judge will hear evidence from the Division and the company to determine whether the allegations of the Division contained in the Order, which the Division alleges constitute failures to comply with Exchange Act Section 13(a) and Rules 13a-1 and 13a-13 there under, are true. The judge in the proceeding will then determine whether the registrations pursuant to Exchange Act Section 12 of each class of the securities of the company should be revoked or suspended for a period not exceeding twelve months. The Commission ordered that the Administrative Law Judge in this proceeding issue an initial decision not later than 120 days from the date of service of the order instituting proceeding.

Similar Private Companies By Industry

Company Name Region
Mylan Pharmaceuticals Inc. United States
The Rugby Group, Inc. United States
GLG Pharma, LLC United States
PPD Global Central Labs, LLC United States
The Clinical Research Center United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Ceragenix Pharmaceuticals, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at